Physician profile
Azhar Malik
NPI 1609872670
$1,491.54
in general payments reported to CMS, 2019-2025
19 companies · $944 in 2025
The $944 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.73 · 2021: $30.46 · 2022: $16.64 · 2023: $146 · 2024: $309 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.11 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.11 | 2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $144.21 | 2025 | |
| Novo Nordisk INC | $136.95 | 2024-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.41 | 2023-2025 | Jardiance |
| Vantive US Healthcare LLC | $115.87 | 2025 | Renal - Acute |
| Calliditas Therapeutics US INC. | $113.81 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $96.25 | 2021-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $94.83 | 2021-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $86.29 | 2025 | |
| Mallinckrodt Hospital Products INC. | $63.21 | 2025 | Terlivaz, Acthar |
| Ardelyx, INC. | $60.77 | 2024-2025 | Ibsrela |
| Scpharmaceuticals INC. | $52.31 | 2025 | |
| Akebia Therapeutics INC | $48.04 | 2019-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $45.49 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $45.27 | 2023 | Lupkynis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $43.98 | 2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $26.56 | 2024 | |
| Bard Peripheral Vascular, INC. | $24.09 | 2019 | |
| Glaxosmithkline, LLC. | $16.09 | 2025 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azhar Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.